Back to catalogue
№ 077 20 filings · 2021-09-15 → 2026-07-28

BRIDGEPOINT GROUP PLC

BPT
Financial Services Share price 309p Market cap £2.9bn Overall fit 605 /1000

Genuine operating leverage and a fair-to-cheap valuation for a scaled alts manager, with meaningful indirect AI exposure through ECP's US power/data-centre infrastructure, offset by only-indirect AI angle (the group captures fee/carry, not the AI cashflow) and ongoing PE-cycle sensitivity.

Fair value range 450p–560p Mid case · £4.5bn
Absolute upside +56.4% vs current market cap
Conviction 3/5 confidence in undervalued call
Supports the call
  • Consistent guidance-beat track record
  • Fee-paying AUM step-up is contractually visible
  • Clean peer multiple comparison to EQT/Ares/Partners Group
Limits the call
  • Meaningful dilution from KARE consideration and ECP earn-out shares
  • Wide reported-vs-underlying earnings gap requires trust in adjustments
Methodology

Forward P/E on underlying EPS with listed peer cross-check

In one line · bull case

Locked-in FRE step-up from three flagship funds simultaneously reaching fee-paying status, plus a >20% EPS-accretive KARE deal, at a P/E discount to global alt-manager peers.

In one line · biggest risk

Substantial dilution from ECP earn-outs and up to ~292m KARE-related shares could dampen per-share earnings accretion if fundraising or fund performance disappoints.

Drivers
AI beneficiary 45 /100
Not a direct AI receiver, but ECP's US energy-transition/gas-turbine assets (partnership with KKR on data centres, ProEnergy order book) are materially exposed to AI-driven power demand.
Operating leverage 75 /100
70%+ fixed cost base; H1 2026 FRE margin jumped 580bp to 42.5% on 23% underlying fee growth; PRE line is highly geared to fund exit cadence.
Earnings vs expectations 75 /100
Consistent beats and raises across every reporting period covered — 2024 FY, both 2025 halves, both 2026 halves.
Growth momentum 75 /100
AUM up 24.5% in 2025, FPAUM up 33% in H1 2026, multiple fundraising records, PRE more than doubled H1 2026 vs H1 2025.
Moat 60 /100
Middle-market brand and scale, sticky LP relationships (38 of top 50 global LPs), but no true switching cost — moat is execution-based.
Earnings quality 60 /100
Underlying EPS is defensible but gap to IFRS reported earnings is wide (£150m in H1 2026) due to ECP/KARE transaction costs and CLO consolidation adjustments.
Management quality 70 /100
Long-tenured team, disciplined M&A record (EQT Credit, ECP, Newbury, KARE), candid disclosure, staggered lock-ups aligning insiders long-term.
Cyclicality 60 /100
Fee income is highly visible from multi-year fund contracts, but PRE and fundraising are exposed to PE cycle and denominator effect (as flagged in 2022).
Leverage 30 /100
Net debt 0.7x LTM EBITDA at H1 2026, peaking at ~2x post-KARE with rapid deleveraging expected — a fortress-ish balance sheet.

Bridgepoint Group plc (BPT) — Investment Research Note

Executive summary

Bridgepoint is a UK-listed, mid-market focused alternative asset manager with $97bn AUM across private equity, credit, US energy-transition infrastructure (ECP) and — post-2026 — real estate (KARE). The trajectory over the covered period is one of rapid scaling: AUM has more than tripled since the 2021 IPO (from ~€19bn to $97bn), fee-paying AUM grew 33% year-on-year to $58.4bn in H1 2026, and underlying EBITDA jumped 78% year-on-year in H1 2026 to £227m on a 60.6% margin. The single most important valuation point today is that the current share price (339p) values the group on roughly 11x 2026E underlying EPS despite a materially improving fee-earning base (BE VIII becoming fee-paying, ECP VI, plus KARE closing at year-end 2026 which is guided to be >20% EPS accretive in 2028) — the market has re-rated the stock ~50% off the March low but still sits below the pre-fundraise cycle floor.

Fair value estimate

  • Methodology: blended forward P/E on underlying EPS with cross-check to peer FRE multiples. This is the standard approach for listed alternative asset managers.
  • Assumptions (central case): 2026E underlying diluted EPS of ~28p (annualising H1 2026's 15.5p, adjusting for the guided H2 PRE step-down); 2027E of ~34p standalone + KARE full-year contribution; 2028E EPS in the 40–45p range including >20% KARE accretion. Applying 14–17x forward EPS (below the 20–25x range for scaled listed peers like EQT, Ares, Partners Group, reflecting more modest disclosure and PE-cycle risk).
  • Fair value range: 450p – 560p per share, mid ~505p.
  • Implied market cap at midpoint: ~£4.5bn (vs current £3.0bn), using ~890m shares outstanding and ignoring the KARE Consideration Shares that also brought incremental earnings.
  • Absolute upside vs current 339.4p: ~+49% at midpoint (range +33% to +65%).

Sector context

Financial Services / Alternative Asset Managers. Bridgepoint sits in the premium end of the sector — 60% EBITDA margins, high fee visibility (~13–16% multi-year management fee growth guided), and a strong track record. Growth and margin profile is above typical UK financials peers and roughly in line with global listed alts. Listed peers: EQT AB, Partners Group, Ares Management (larger, US-focused), and to a lesser extent Intermediate Capital Group and Petershill Partners. Bridgepoint trades at a material discount to EQT/Ares/Partners Group on forward P/E despite comparable growth.

Investment thesis

  1. Locked-in step-up in fee-related earnings from three flagship fund cycles finishing simultaneously. BE VIII (€8–8.5bn expected), ECP VI ($7.8bn hard cap), BDL IV (€5.1bn already closed) plus KARE closing at year-end 2026 collectively drive a mechanical increase in fee-paying AUM into 2027 with visibility "13–16% mgmt fee growth on a rolling 3-year basis" 2026-07 half-year.
  2. KARE acquisition is EPS accretive and adds a highly cash-generative real-estate vertical at a mid-single-digit 2028 EBITDA multiple; guided to be >20% EPS accretive in 2028 with EBITDA margin trending to 60%+ post-integration 2026-06-29 KARE announcement.
  3. ECP's US energy-transition/infrastructure business is a genuine indirect AI-power beneficiary — the KKR data-centre partnership and ProEnergy's gas-turbine order book explicitly reference AI-driven electricity demand, and ECP V is marked at 3x MOIC less than three years into vintage, driving PRE recognition earlier than planned 2026-07 half-year; 2025-03 FY.

Key risks

  1. PE-cycle risk on fundraising and exits — if institutional appetite for private markets fatigues, or the denominator effect returns, next-cycle fundraising (BE VIII, ECP VII in 2029) could disappoint the €28bn/€24bn/€20bn targets management has been consistently upgrading 2025-11 secondary placing announcement; historic 2022 Q3 trading update flagged denominator effect.
  2. Substantial dilution and lock-up expiries — the ECP deal added ~185m partnership units (some subject to vesting/earn-out); the KARE deal will add up to ~292m Bridgepoint-equivalent shares (Consideration + earn-out + awards) 2026-06-29 KARE announcement; the final IPO lock-up on ~61m shares released July 2026 in an oversubscribed placing at 316p 2026-07-28 placing result. Dilution risk is real and needs to be modelled.
  3. Reported vs underlying earnings gap — H1 2026 reported PBT of £42.9m vs underlying PBT of £197.5m, driven by £101.7m of exceptionals (mostly ECP/KARE transaction and share-based payments) plus £24m intangible amortisation. The gap is defensible but requires trust in the adjustments 2026-07 half-year.

Operating leverage

Bridgepoint has high but somewhat capped operating leverage. Roughly 70–75% of the cost base is fixed personnel and infrastructure. When BE VIII started fee-paying on 9 June 2026, FRE margin jumped from 36.7% in H1 2025 to 42.5% in H1 2026 (a +580bp move) on 22.8% underlying fee growth — meaning ~50% of incremental revenue dropped to FRE. Management explicitly guides EBITDA margin to 55–60% in 2026/27 as the current fundraising cycle completes and FRE margin should trend to 35% steady-state until BE VIII scales further 2026-07 half-year; 2025-07 half-year. A 10–20% revenue beat above plan (e.g. from BE VIII closing at €8.5bn hard cap plus faster ECP VI deployment) would plausibly add ~40–50% to underlying EBITDA — a meaningful but not extreme leverage. The bigger long-tail: PRE (carried interest) is materially operationally-geared — H1 2026 PRE grew 109% to £120.7m and the first carry from ECP V was recognised, three years earlier than planned. Successful realisations across the ECP V and BE VII portfolios could drive PRE well above the guided 20–25% of total income.

Value-trap signals

None identified. Revenue and FRE growing double-digit, guidance repeatedly raised (24 to 28 to eventually >€28bn fundraising target across successive updates), dividend growing (interim raised from 4.6p to 4.8p), net leverage a modest 0.7x LTM EBITDA rising to peak ~2x post-KARE, credit facilities recently upsized. The insider secondary placings in Nov 2025 (24m shares at 275p) and July 2026 (19.7m shares at 316p) are lock-up-driven, not distress signals — the July 2026 placing priced at a premium to earlier tranches.

Earnings vs expectations

  • H1 2026: Ahead of consensus (own compiled). Guidance for 2026 fundraising raised to €28bn from €24bn in June; H1 EBITDA of £227m came in "ahead of expectations" per management. Beat.
  • FY 2025 (March 2026): Underlying EBITDA £304.8m, ahead of guidance; PRE 27% of total income vs 20–25% guided range. Beat.
  • H1 2025 (July 2025): In line to slightly ahead, guidance raised on FRE margin (to ~37%) and PRE (~25% of income). Beat.
  • FY 2024: Strong performance driven by ECP transaction closing plus catch-up fees on BE VII/ECP V. Beat.
  • H1 2024: Ahead of expectations, driving upgrades to full-year guidance. Beat.

The pattern is consistent beats and guidance raises over the covered period, with catch-up fees regularly providing upside. This is a positive earnings surprise track record.

Conviction: 3 (moderate)

Supports: consistent record of guidance beats and raises; clean underlying accounting once CLO consolidation and transaction exceptionals are stripped out; peer group provides valid multiple anchoring; fee-paying AUM step-up is contractually locked in. Limits: significant dilution assumptions in the fair value (KARE consideration shares, ECP earn-outs); reported vs underlying gap of ~£150m in H1 2026 requires the adjustments to be taken on faith; PE cycle sensitivity to exit environment for the PRE line.

Filings consulted · 27

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-07-28Results OF Secondary Placing2026-07-28_9689919_results-of-secondary-placing.md0.70
  2. 2026-07-27Proposed Secondary Placing OF Ordinary Shares2026-07-27_9689677_proposed-secondary-placing-of-ordinary-shares.md0.70
  3. 2026-07-17Half Year Report2026-07-17_9673554_half-year-report.md0.90
  4. 2026-06-29Acquisition OF Kane Anderson Real Estate2026-06-29_9640400_acquisition-of-kane-anderson-real-estate.md0.75
  5. 2026-05-12Result OF Agm2026-05-12_9564802_result-of-agm.md0.30
  6. 2026-03-26Annual Report And Accounts And Notice OF Agm2026-03-26_9493719_annual-report-and-accounts-and-notice-of-agm.md0.95
  7. 2026-03-12Final Results2026-03-12_9470358_final-results.md1.00
  8. 2025-11-14Results OF Secondary Placing2025-11-14_9232977_results-of-secondary-placing.md0.59
  9. 2025-11-13Proposed Secondary Placing OF Ordinary Shares2025-11-13_9232477_proposed-secondary-placing-of-ordinary-shares.md0.59
  10. 2025-07-18Half Year Report2025-07-18_8985763_half-year-report.md0.58
  11. 2025-05-15Result OF Agm2025-05-15_8880913_result-of-agm.md0.20
  12. 2025-03-26Annual Report And Accounts And Notice OF Agm2025-03-26_8797077_annual-report-and-accounts-and-notice-of-agm.md0.62
  13. 2025-03-13Final Results2025-03-13_8776789_final-results.md0.65
  14. 2024-10-24Capital Markets Day2024-10-24_8505232_capital-markets-day.md0.62
  15. 2024-07-19Half Year Report2024-07-19_8320853_half-year-report.md0.41
  16. 2024-07-15Update ON Financing Acquisition OF Alpha Fmc2024-07-15_8310066_update-on-financing-acquisition-of-alpha-fmc.md0.34
  17. 2024-05-15Result OF Agm2024-05-15_8199534_result-of-agm.md0.14
  18. 2024-04-18Notice OF Agm2024-04-18_8144869_notice-of-agm.md0.14
  19. 2024-03-212023 Annual Report And Accounts2024-03-21_8100172_2023-annual-report-and-accounts.md0.43
  20. 2024-03-14Final Results2024-03-14_8086854_final-results.md0.45
  21. 2023-05-18Result OF Agm2023-05-18_7533279_result-of-agm.md0.07
  22. 2023-03-24Annual Report And Accounts And Notice OF Agm2023-03-24_7280313_annual-report-and-accounts-and-notice-of-agm.md0.24
  23. 2022-11-16Trading Statement2022-11-16_7374222_trading-statement.md0.21
  24. 2022-05-13Result OF Agm2022-05-13_6888603_result-of-agm.md0.07
  25. 2022-03-30Annual Report And Accounts And Notice OF Agm2022-03-30_7093914_annual-report-and-accounts-and-notice-of-agm.md0.24
  26. 2021-11-16Quarterly Trading Update2021-11-16_6739485_quarterly-trading-update.md0.21
  27. 2021-09-15Half Year Update 20212021-09-15_6827261_half-year-update-2021.md0.23

This research note was authored by a large language model after reading 20 regulatory filings published between 2021-09-15 and 2026-07-28. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.